People with autism are asserting their right to be different. They say so-called ‘neurotypicals’ are the ones with communication problems, relying on the ‘animalistic means’ of body language, and they don’t understand why their focused, repetitive behaviors are thought to be problematic when neurotypicals indulge in obsessions such as sports and soap operas.
Spectrum: Autism Research News
Efforts to ease the symptoms of autism are beginning to ramp up, with promising candidates in various stages of testing.
If you believe the hype about oxytocin, it’s nothing short of a wonder drug: it can make you trust a stranger, enhance a mother’s bond with her child and, according to a study published earlier this year, improve social skills in individuals with autism. But look more closely, and there is ample cause for caution.
With robust training in developmental psychology and a techie’s fervor for new tools, Kevin Pelphrey is systematically investigating how the brain changes during development — starting in infants as young as 6 weeks old.
Not all stem cells are created equal, a string of new studies suggests: adult cells that are reprogrammed into stem cells carry chemical remnants of the tissue from which they originate, making them distinct from embryonic stem cells. These differences may have important implications for studying fragile X syndrome and other diseases that arise from epigenetic glitches.
Scientists have for the first time captured a dynamic picture of brain defects in young mouse models of fragile X syndrome. The findings appeared in June in the Journal of Neuroscience.
Scientists have discovered that neurexins — proteins linked to autism — bind to a wide variety of molecules at the junction between neurons. In this complicated system, the breakdown of any one of the parts could lead to improper cell signaling, ultimately giving rise to disease.